Healthcare Sales & Marketing Network News: ALK

Searching News Database: ALK

HSMN NewsFeed - 20 Jul 2026
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 11 May 2026
Partner Therapeutics Announces FDA Approval of BIZENGRI(R) (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 7 Oct 2024
ALK Announces U.S. FDA Approval of New AccuTest(TM) Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
Diagnostics FDA

HSMN NewsFeed - 4 Oct 2024
Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life
Devices Drug Delivery Product Recall

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Mar 2024
Ventris Medical Receives 510(k) Additional Clearance for Amplify(R) Standalone Bone Graft Putty
Devices FDA

HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Feb 2024
AbbVie Completes Acquisition of ImmunoGen
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Aug 2023
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
Biopharmaceuticals Litigation Licensing

HSMN NewsFeed - 13 Sep 2022
Ventris Medical Receives 510(k) Clearance for Amplify(R) Standalone Bone Graft Putty and Bone Graft Extender
Devices Regenerative Medicine FDA

HSMN NewsFeed - 20 Jul 2022
Nuvalent Announces Leadership Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Apr 2022
Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Nov 2021
Kintara Announces Changes to Executive Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Nov 2021
FDA Grants Profounda Orphan Drug Designation Approval for Treatment of Invasive Candidiasis with Miltefosine
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Oct 2021
U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Aug 2021
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 May 2021
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2021
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Nov 2020
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 30 Sep 2020
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2020
Orfadin(R) (nitisinone) receives positive opinion from CHMP for treatment of AKU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Dec 2019
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Dec 2019
FDA clears Cochlear's innovative new Osia(R) 2 hearing implant system
Devices FDA

HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Nov 2019
Alkermes Completes Acquisition of Rodin Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 13 Sep 2019
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
Biopharmaceuticals Oncology Neurology Personnel

HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2019
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2019
U.S. FDA Approves GATTEX(R) (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 22 Apr 2019
Neurelis Announces Completion of Senior Management Team Buildout to Support the Anticipated Commercial Launch of VALTOCO(TM)
Biopharmaceuticals Drug Delivery Neurology Personnel

HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 2 Jan 2019
LIGHTMED Corporation Founder and Executive Chairman Gary Lee Reassumes CEO Role
Devices Ophthalmology Dermatology Personnel

HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory

HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Sep 2018
Johnson & Johnson Vision Launches Next Generation of Personalized LASIK Treatment, iDESIGN Refractive Studio Now Available
Devices Ophthalmology FDA Product Launch

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Mar 2018
LIGHTMED Corporation Appoints Dennis Dowell as Director of Sales and Marketing for North America
Devices Ophthalmology Personnel

HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2018
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
Biopharmaceuticals Licensing

HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Sep 2017
LIGHTMED Corporation Appoints Shlomo Alkalay as CEO
Devices Ophthalmology Personnel

HSMN NewsFeed - 7 Aug 2017
Alkahest Appoints Helen Jenkins as Chief Operating Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Jun 2017
FDA Grants Profounda Inc. Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2017
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Diagnostics Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 May 2017
NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2017
ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX(R) in Europe)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Feb 2017
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
Diagnostics Oncology Regulatory

HSMN NewsFeed - 25 Jan 2017
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Biopharmaceuticals

HSMN NewsFeed - 23 Jan 2017
Alkahest Appoints Sam Jackson, M.D., MBA as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2017
Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Biopharmaceuticals

HSMN NewsFeed - 6 Jan 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Dec 2016
FDA Orphan Drug Designation Granted to Profounda Inc. for the Treatment of Acanthamoeba Keratitis with Miltefosine
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 23 Nov 2016
Neurotrope Issues Statement On Eli Lilly's Solanezumab
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Sep 2016
Dr. Daniel Alkon Appointed President of Neurotrope, Inc.
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 28 Sep 2016
Assembly Biosciences Announces Key Additions to Microbiome Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2016
Elite Announces Development and License Agreement with SunGen Pharma LLC
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 3 Aug 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Jul 2016
Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2016
NuVasive Launches Next Generation Biologics Technology
Devices Orthopaedic Neurosurgery Product Launch

HSMN NewsFeed - 9 May 2016
Elite Pharmaceuticals to Present SequestOx(TM) Data at the American Pain Society 35th Annual Scientific Meeting
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 9 May 2016
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Biopharmaceuticals

HSMN NewsFeed - 4 May 2016
Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Apr 2016
Enterome Raises EUR14.5 Million in Series C Financing Round
Biopharmaceuticals Gastroenterology Venture Capital

HSMN NewsFeed - 14 Apr 2016
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Biopharmaceuticals

HSMN NewsFeed - 12 Apr 2016
Elite Pharmaceuticals Announces Changes to their Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA

HSMN NewsFeed - 17 Mar 2016
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Feb 2016
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola(R)
Biopharmaceuticals Urology

HSMN NewsFeed - 2 Feb 2016
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 13 Jan 2016
Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2015
Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Oct 2015
Recro Pharma Provides Pipeline Update
Biopharmaceuticals

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2015
ETView and The University of Texas MD Anderson Cancer Center (Houston, TX) Announce the Start of a Prospective, Randomized Clinical Evaluation of VivaSight-DL(TM) vs. Standard Double-Lumen Endotracheal Tubes
Devices

HSMN NewsFeed - 2 Sep 2015
Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
Diagnostics Venture Capital

HSMN NewsFeed - 14 Jul 2015
SSCOR Introduces Industry's First D Cell-Powered Portable Suction Device
Devices Product Launch

HSMN NewsFeed - 7 Jul 2015
Abingworth Appoints Tim Haines and Kurt von Emster as Joint Managing Partners
Biopharmaceuticals Devices Venture Capital Personnel

HSMN NewsFeed - 6 Jul 2015
Strensiq(R) (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jun 2015
Spero Completes $30 Million Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel

HSMN NewsFeed - 24 Oct 2014
Elite Pharmaceuticals Announces New Management Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Oct 2014
Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announces European site initiation of Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Sep 2014
Eisai Sells U.S. Rights to Zonegran(R) (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 24 Jun 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2014
Enterome Raises €10 million in Series B Fund Raising
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Mar 2014
Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT(R) (vintafolide) and Companion Imaging Agents FOLCEPRI(R) (etarfolatide) and NEOCEPRI(R) (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology Radiology Regulatory

HSMN NewsFeed - 13 Mar 2014
Tetraphase Pharmaceuticals Adds Nancy J. Wysenski to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Feb 2014
Pernix Attracts $65 Million Institutional Investment; Appoints Doug Drysdale as CEO; Settles Pending Legal Liabilities
Biopharmaceuticals Personnel Litigation

HSMN NewsFeed - 3 Feb 2014
Merck Announces Canadian Approval of GRASTEK(R) (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jan 2014
Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children
Diagnostics FDA

HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 8 Oct 2013
Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Sep 2013
Alkermes Expands Senior Management Team
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 11 Sep 2013
Civitas Therapeutics Secures $38 Million in Financing
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 12 Aug 2013
Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2013
Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim asElite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and Chief Executive Officer President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jul 2013
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 26 Mar 2013
Acceleron Receives Two FDA Orphan Designations for ACE-536
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 6 Feb 2013
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 31 Jan 2013
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jan 2013
Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury
Biopharmaceuticals Neurology Neurosurgery

HSMN NewsFeed - 21 Dec 2012
FDA Approves Gattex(R) (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 21 Dec 2012
Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Dec 2012
Premier healthcare alliance Names Gary Long Chief Sales Officer
Devices Group Purchasing Personnel

HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 9 Oct 2012
Acorda Therapeutics Names Jane Wasman President, International
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2012
Civitas Therapeutics Appoints Bryan E. Stuart Chief Business Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 4 Sep 2012
Pulmatrix Appoints Robert Clarke, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Formula Pharmaceuticals Appoints Morton Collins to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Mar 2012
Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 5 Mar 2012
Alkermes Appoints Mark Stejbach as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2012
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
Diagnostics Oncology Personalized Medicine

HSMN NewsFeed - 23 Dec 2011
Acceleron Secures $30M Private Financing
Biopharmaceuticals Mergers & Acquisitions Personnel

HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Diagnostics FDA

HSMN NewsFeed - 28 Sep 2011
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Sep 2011
Elan Announces Board of Director Changes
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 6 Sep 2011
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials With A New Brain Cancer Treatment
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Aug 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
Diagnostics Personalized Medicine Oncology FDA

HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA

HSMN NewsFeed - 29 Jun 2011
Pulmatrix Promotes Robert Clarke, PhD, to Chief Scientific Officer and Vice President of Research and Development
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 21 Jun 2011
Bydureon Receives Marketing Authorization in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2011
Alkermes to Merge with Elan Drug Technologies to Create Alkermes plc
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Apr 2011
BYDUREON Recommended for Approval in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 22 Mar 2011
TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 22 Feb 2011
Erica L. Mann, Former Pfizer Executive, Appointed New President of Bayer HealthCare's Global Consumer Care Division
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Biopharmaceuticals Diagnostics Personalized Medicine

HSMN NewsFeed - 10 Jan 2011
Civitas Therapeutics Secures $20 Million Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 3 Dec 2010
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Nov 2010
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Sep 2010
Cell Therapeutics to Appeal FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jun 2010
Siemens Launches SIERRA Dose Reduction Initiative in Computed Tomography
Devices Radiology

HSMN NewsFeed - 14 Jun 2010
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2010
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2010
Dr. John Mendlein Joins aTyr Pharma as Executive Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 9 Apr 2010
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Biopharmaceuticals

HSMN NewsFeed - 5 Mar 2010
SurModics Announces Organizational and Leadership Changes
Devices Personnel

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 22 Dec 2009
Acceleron Pharma Expands Management Team with Two New Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Nov 2009
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2009
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Sep 2009
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jul 2009
aTyr Pharma Raises an Additional $12 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Jul 2009
Embera NeuroTherapeutics Announces Expansion of Management Team after Successful Completion of Pilot Study of Cocaine Addiction Treatment
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Jul 2009
Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
Devices Cardiology Regulatory

HSMN NewsFeed - 8 Jul 2009
Covidien Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement and Innovation
Devices Surgery Group Purchasing

HSMN NewsFeed - 19 Jun 2009
I-Therapeutix, Inc. Closes $15 Million Financing
Devices Ophthalmology Venture Capital

HSMN NewsFeed - 27 May 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 15 May 2009
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 May 2009
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 27 Apr 2009
RISPERDAL CONSTA Approved in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Mar 2009
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Feb 2009
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2008
Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Dec 2008
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2008
Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2008
Lilly Launches New FORTEO Delivery Device
Biopharmaceuticals Devices Drug Delivery

HSMN NewsFeed - 22 Sep 2008
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Aug 2008
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Aug 2008
Follica Announces $11M in New Financing and Expanded Team
Devices Personnel Venture Capital

HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jul 2008
Lilly to Acquire SGX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 30 Jun 2008
Akesis Pharmaceuticals Names Carl LeBel as President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jun 2008
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2008
Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 2 Jun 2008
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
Devices Group Purchasing

HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
Santarus Announces Development Program for New ZEGERID Prescription Product
Biopharmaceuticals

HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2008
ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 May 2008
MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Apr 2008
Premier Healthcare Alliance Adds New Members with $1.1 Billion in Purchasing Volume in 2007
Devices Group Purchasing

HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Apr 2008
New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
Devices Wound Care

HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Mar 2008
Alkermes Announces Restructuring
Biopharmaceuticals

HSMN NewsFeed - 7 Mar 2008
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
Biopharmaceuticals Drug Delivery Endocrinology

HSMN NewsFeed - 7 Mar 2008
Lilly Announces Termination of AIR Insulin Program
Biopharmaceuticals Endocrinology Drug Delivery

HSMN NewsFeed - 7 Mar 2008
Alkermes Provides Update on Inhaled Insulin Program
Biopharmaceuticals Drug Delivery Endocrinology

HSMN NewsFeed - 4 Mar 2008
Targanta Strengthens Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Feb 2008
Ireland Cancer Center and TRACON Pharmaceuticals Announce Treating the First Cancer Patient With TRC102, An Inhibitor of Chemotherapy Resistance
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Feb 2008
Ceremed Appoints Vice President for Sales and Business Development
Devices Personnel

HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2008
Santarus Announces Launch of ZEGERID Products by GlaxoSmithKline in Puerto Rico and U.S. Virgin Islands
Biopharmaceuticals

HSMN NewsFeed - 18 Feb 2008
Paladin Labs & KV Pharmaceuticals Sign Distribution For Micro-K(R) Extencaps(R) Capsules
Biopharmaceuticals Distribution

HSMN NewsFeed - 11 Feb 2008
Spectrum Pharmaceuticals Strengthens Management; Appoints Oncologist Richard A. Bender, MD as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Feb 2008
Ceremed's OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
Devices Surgery

HSMN NewsFeed - 4 Feb 2008
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Feb 2008
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Jan 2008
NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
Devices Surgery Licensing

HSMN NewsFeed - 8 Jan 2008
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Biopharmaceuticals

HSMN NewsFeed - 7 Jan 2008
Santarus Announces Positive Clinical Results with ZEGERID Capsules in Controlling Gastric Acidity over 24 Hours
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Dec 2007
Santarus Licenses Rights to GlaxoSmithKline for ZEGERID Immediate-Release Omeprazole Products in over 100 Countries
Biopharmaceuticals Distribution Licensing

HSMN NewsFeed - 27 Nov 2007
BIND Biosciences, Inc. Closes $16M Series B Financing Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Nov 2007
Orexo Announces New Executive Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Nov 2007
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 30 Oct 2007
Acceleron Pharma Completes $31M Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 24 Oct 2007
Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 11 Oct 2007
St. Jude Medical Awarded Contract for Cardiac Rhythm Management Devices
Devices Cardiology Group Purchasing

HSMN NewsFeed - 10 Oct 2007
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2007
Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
Biopharmaceuticals Personnel Drug Delivery

HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Sep 2007
BIOTRONIK Awarded Major Cardiac Rhythm Management Contract
Devices Cardiology Group Purchasing

HSMN NewsFeed - 18 Sep 2007
Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
Biopharmaceuticals

HSMN NewsFeed - 11 Sep 2007
Enobia Pharma Raises $40.1 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Sep 2007
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Biopharmaceuticals Cardiology

HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Aug 2007
Newly Created Hemosol BioPharma Inc. on the Hunt for Partnership, Licensing and Acquisition Targets
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Jul 2007
Alnylam Expands Management Team with New Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2007
Premier's Spine Implant Portfolio Produces $30 Million in Member Savings During First Year
Devices Neurosurgery Orthopaedic Group Purchasing

HSMN NewsFeed - 12 Jul 2007
Physicians at the University of California, San Diego Treat Trigeminal Neuralgia Using Trilogy(TM) Technology for Image-Guided Radiosurgery from Varian Medical Systems
Devices Neurosurgery

HSMN NewsFeed - 8 Jul 2007
New Study Shows That Extending Prophylaxis With Clexane(R) / Lovenox(R) (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2007
Cytokinetics Announces Second Extension of Research Term Under Collaboration With GlaxoSmithKline
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine(R) (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
AcroMetrix Receives 510(k) Clearance for VeriSure(R) Pro HBV Blood Screening Controls
Diagnostics FDA

HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2007
Vion Announces Suspension of Phase III Trial in Relapsed AML
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 May 2007
Solace Pharmaceuticals Raises $15M in Series A Financing; Names Senior Pfizer Executive as CEO
Biopharmaceuticals Personnel Venture Capital

HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Apr 2007
Dr. James Tanguay Joins Vion Pharmaceuticals' Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Mar 2007
Introducing New ALEVE(R) Liquid Gels
Biopharmaceuticals

HSMN NewsFeed - 6 Mar 2007
Acusphere Announces Key Promotions in Research and Development
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 5 Mar 2007
Alkermes Announces Senior Management Succession Plan
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Feb 2007
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2007
FDA-approved Ostene, Made by Ceremed Inc. and Designed for Use in Cardiac Surgery, May Reduce Serious Post-operative Complications in Heart Patients
Devices Surgery

HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2007
NCCN Updates Multiple Myeloma Guidelines
Oncology

HSMN NewsFeed - 8 Jan 2007
Alkermes and Lilly Expand AIR(R) Inhaled Insulin Collaboration
Biopharmaceuticals Endocrinology Drug Delivery Licensing

HSMN NewsFeed - 4 Jan 2007
Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Dec 2006
Vion Pharmaceuticals Enters Into Manufacturing Agreement for Cloretazine(R) (VNP40101M) With Ben Venue Laboratories
Biopharmaceuticals

HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 13 Nov 2006
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Oct 2006
Vion Pharmaceuticals Presents Initial Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Oct 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC)
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Oct 2006
Abaxis Announces CLIA Waived Status
Diagnostics FDA

HSMN NewsFeed - 18 Oct 2006
Santarus Licenses OTC Rights to Lower Dosage Immediate-Release ZEGERID Products to Schering-Plough
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Oct 2006
OREXIGEN(TM) Therapeutics Expands Senior Management Team as Lead Products Advance Through Late-Stage Clinical Trials
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Sep 2006
Physicians at the University of California, San Diego Deliver Non-Invasive Neurosurgery Using Image-Guidance Tools From Varian Medical Systems
Devices Oncology Neurosurgery

HSMN NewsFeed - 18 Sep 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jul 2006
Aileen Ryan Joins Vion Pharmaceuticals' Senior Management Team
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
Vion Initiates Pivotal Phase II Trial of Single Agent Cloretazine(R) in Elderly Patients with De Novo Poor-Risk Acute Myelogenous Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 May 2006
New Stroke Guidelines Underscore Importance of Aspirin for Women
Biopharmaceuticals Neurology

Return to NewsFeed

Additional items found! 177

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 177 additional stories matching:
ALK
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!